Ramoril 1.25 mg

Hypertension. Symptomatic heart failure, including after myocardial infarction. Reduction of cardiovascular risk in high-risk patients. Diabetic and non-diabetic kidney disease with proteinuria.

Ramipril is a prodrug converted to ramiprilat, which inhibits angiotensin converting enzyme (ACE). This reduces formation of angiotensin II and aldosterone, dilating blood vessels, lowering blood pressure and reducing the workload of the heart.

Hypertension: start with 1.25-2.5 mg once daily; usual maintenance 2.5-5 mg once daily, maximum 10 mg daily. Heart failure: start with 1.25 mg once daily and increase gradually to a maximum of 10 mg daily. Cardiovascular risk reduction: start with 2.5 mg once daily, increased gradually to 10 mg once daily.

Persistent dry cough, dizziness, headache, low blood pressure, fatigue, raised blood potassium and changes in kidney function. Angioedema (swelling of the face, lips or throat) is rare but serious.

The first dose may cause a marked fall in blood pressure, particularly in patients on diuretics. Monitor kidney function and potassium. Stop the drug and seek help at once if swelling of the face or throat occurs.

History of angioedema, pregnancy, hypersensitivity to ACE inhibitors, bilateral renal artery stenosis, use with sacubitril/valsartan, and use with aliskiren in patients with diabetes or renal impairment.

Store below 30°C in a cool, dry place, away from light. Keep out of the reach of children.